Evidence map›Paper›PMID 24553146›Full record

ArticleEuropean journal of medicinal chemistry2014

Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions.

Liang Kou, Mei-Juan Wang, Li-Ting Wang, Xiao-Bo Zhao, Xiang Nan, Liu Yang, Ying-Qian Liu, Susan L Morris-Natschke, Kuo-Hsiung Lee

Abstract read
In one paragraph

Article in European journal of medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Nitroxides as Antioxidants and Anticancer Drugs.International journal of molecular sciences · 2017
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liang KouSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Mei-Juan WangSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Li-Ting WangNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Xiao-Bo ZhaoSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Xiang NanSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China.
Liu YangEnvironmental and Municipal Engineering School, Lanzhou Jiaotong University, Lanzhou 730000, PR China.
Ying-Qian LiuSchool of Pharmacy, Lanzhou University, Lanzhou 730000, PR China; Xinjiang Production & Construction Corps Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin, PR China. Electronic address: yqliu@lzu.edu.cn.
Susan L Morris-NatschkeNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Kuo-Hsiung LeeNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA; Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan. Electronic address: khlee@email.unc.edu.

Funding

Novel Antitumor AgentsR01CA177584 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, KUO-HSIUNG · 2013 to 2017
$1.9M
NCI NIH HHS CA177584NCI NIH HHS R01 CA177584
6 · The paper itself

Abstract

Spin-labeled podophyllotoxins have elicited widespread interest due to their far superior antitumor activity compared to podophyllotoxin. To extend our prior studies in this research area, we synthesized a new generation of spin-labeled podophyllotoxin analogs via isocyanide multicomponent reactions and evaluated their cytotoxicity against four human cancer cell lines (A-549, DU-145, KB and KBvin). Most of the compounds exhibited potent cytotoxic activity against all four cell lines, notably against the drug resistant KBvin cancer cell line. Among the new analogs, compounds 12e (IC50: 0.60-0.75 μM) and 12h (IC50: 1.12-2.03 μM) showed superior potency to etoposide (IC50: 2.03 to >20 μM), a clinically available anticancer drug. With a concise efficient synthesis and potent cytotoxic profiles, compounds 12e and 12h merit further development as a new generation of epipodophyllotoxin-derived antitumor clinical trial candidates.

Indexed as

Antineoplastic AgentsCell Line, TumorCyanidesDrug Screening Assays, AntitumorEtoposideHumansNeoplasmsPodophyllotoxinSpin LabelsStructure-Activity RelationshipAntineoplastic AgentsCyanidesEtoposidePodophyllotoxinSpin LabelsC-4 positionCytotoxic activityIsocyanide multicomponent reactionsPodophyllotoxinSpin labeled

Identifiers

PMID24553146
PMCPMC3955052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.